Sandoz Reports Robust Q1 2026 Biosimilars Growth Amid Strategic Moves

Sandoz Group AG has announced notable growth in biosimilars for Q1 2026, reporting net sales of USD 2,756 million, an 11% increase from the previous year. Biosimilars saw a significant rise, with net sales surging by 18% at constant currencies, highlighting the division's strength. In contrast, generics reported a 3% decline. Richard Saynor, CEO, reaffirmed the company's 2026 guidance, emphasizing the firm's potential and readiness to capture future opportunities.

Significant geographical performance includes a 12% sales increase in North America, bolstered by biosimilars. Europe saw a 2% growth, while international biosimilars also excelled. A new strategic partnership with Samsung Bioepis aims to enhance up to five biosimilar assets, marking an expansion to 32 pipeline assets.

Sandoz remains optimistic about achieving mid-to-high single-digit sales growth for the year. This outlook aligns with its strategic developments and regulatory benefits, positioning it well for continued success.